Last reviewed · How we verify
Aureomycin (CHLORTETRACYCLINE)
Aureomycin, also known as chlortetracycline, is a small molecule antibiotic in the tetracycline class. It targets protein-arginine deiminase type-4, inhibiting bacterial protein synthesis. Originally developed in the 1940s, it was first approved by the FDA in 1950 for minor bacterial skin infections, neonatal conjunctivitis, and trachoma. As an off-patent medication, it is no longer protected by active patents, allowing generic manufacturers to produce it. Key safety considerations include its potential to interact with other medications and affect gut bacteria.
At a glance
| Generic name | CHLORTETRACYCLINE |
|---|---|
| Drug class | chlortetracycline |
| Target | Protein-arginine deiminase type-4 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1950 |
Approved indications
- Minor Bacterial Skin Infections
- Neonatal conjunctivitis
- Trachoma
Common side effects
Key clinical trials
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy (PHASE2,PHASE3)
- Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy (PHASE1,PHASE2)
- Low Dose Doxycycline in the Treatment of Corneal Burn (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aureomycin CI brief — competitive landscape report
- Aureomycin updates RSS · CI watch RSS